[This corrects the article on p. 2 in vol. 7, PMID: 26834744.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5693906 | PMC |
| http://dx.doi.org/10.3389/fimmu.2017.01524 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Corrigendum to "Induction of glial cell line-derived neurotrophic factor by the squamosamide derivative FLZ in astroglia has neuroprotective effects on dopaminergic neurons" [Brain Res. Bull. 154 (2020) 32-42].
Brain Res Bull
January 2025
State Key Laboratory of Bioactive Substance and Function of Natural Medicine, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Xian Nong Tan Street, Beijing 100050, China; Department of Occupational and Environmental Health, School of Public Health, Dalian Medical University, No. 9 W. Lvshun South Road, Dalian 116044, China. Electronic address:
Corrigendum: Role of β-interferon inducer (DEAE-Dextran) in tumorigenesis by VEGF and NOTCH1 inhibition along with apoptosis induction.
Front Pharmacol
December 2024
Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, India.
[This corrects the article DOI: 10.3389/fphar.2017.
View Article and Find Full Text PDFCorrigendum to "Iron depletion suppresses mTORC1-directed signalling in intestinal Caco-2 cells via induction of REDD1" [Cellular Signalling, 28: (2016) 412-424].
Cell Signal
December 2024
Division of Cell Signalling & Immunology, School of Life Sciences, University of Dundee, Dundee DD1 5EH, UK. Electronic address:
Corrigendum to "Induction of cytotoxicity and apoptosis in FLT3 mutant expressing cells using novel pyrimido cyanoacrylates and quinoline derivatives" [Biomed. Pharmacother. 108 (2018) 893-905].
Biomed Pharmacother
November 2024
Medical Toxicology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address:
Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)": [ESMO Open 7 (2024) 100552].
ESMO Open
October 2024
Department of Internal Medicine II, Medical Oncology and Comprehensive Cancer Center Mainfranken, University Hospital Würzburg, Würzburg. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!